Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Is Surgical Staging Necessary for Patients with Low-risk Endometrial Cancer? A Retrospective Clinical Analysis

  • Kokcu, Arif (Department of Obstetrics and Gynecology, Ondokuz Mayis University) ;
  • Kurtoglu, Emel (Department of Obstetrics and Gynecology, Ondokuz Mayis University) ;
  • Celik, Handan (Department of Obstetrics and Gynecology, Ondokuz Mayis University) ;
  • Kefeli, Mehmet (Department of Pathology, Ondokuz Mayis University) ;
  • Tosun, Migraci (Department of Obstetrics and Gynecology, Ondokuz Mayis University) ;
  • Onal, Mesut (Department of Obstetrics and Gynecology, Ondokuz Mayis University)
  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to compare the tumor-free and overall survival rates between patients with low-risk endometrial cancer who underwent surgical staging and those who did not undergo surgical staging. Materials and Methods: Data, including demographic characteristics, grade of the tumor, myometrial invasion, cervical involvement, peritoneal washing, lymph node involvement, lymphovascular space invasion, postoperative complication, adjuvant treatment, cancer recurrence, and tumor-free and overall survival rates, for patients with low-risk endometrioid endometrial cancer who were treated surgically with and without pelvic and paraaortic lymph node dissection (LND) were analyzed retrospectively. The patients diagnosed with endometrioid endometrial cancer including the following criteria were considered low-risk: 1) a grade 1 (G1) or grade 2 (G2) endometrioid histology; 2) myometrial invasion of <50% upon magnetic resonance imaging (MRI); 3) no stromal glandular or stromal invasion upon MRI; and 4) no evidence of intra-abdominal metastasis. Then the patients at low-risk were divided into two groups; group 1 (n=117): patients treated surgically with pelvic and paraaortic LND and group 2 (n=170): patients treated surgically without pelvic and paraaortic LND. Results: There was no statistical significance when the groups were compared in terms of lymphovascular space invasion, cervical involvement, positive cytology, and recurrence, whereas the administration of an adjuvant therapy was higher in group 2 (p<0.005). The number of patients with positive pelvic nodes and the number of metastatic pelvic nodes were significantly higher in the group with positive LVI than in the group without LVI (p<0.005). No statistically significant differences were detected between the groups in terms of tumor-free survival (p=0.981) and overall survival (p=0.166). Conclusions: Total hysterectomy with bilateral salpingo-oophorectomy and stage-adapted postoperative adjuvant therapy without pelvic and/or paraaortic lymphadenectomy may be safe and efficient treatments for low-risk endometrial cancer.

Keywords

References

  1. Abu-Rustum NR, Alektiar K, Iasonos A, et al (2006). The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at memorial sloan-kettering cancer center. Gynecol Oncol, 103, 714-8. https://doi.org/10.1016/j.ygyno.2006.03.055
  2. Akbayir O, Corbacioglu A, Goksedef BP, et al (2012). The in endometrioid adenocarcinoma of endometrium. Gynecol Oncol, 125, 400-3. https://doi.org/10.1016/j.ygyno.2012.01.051
  3. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009). Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet, 373, 125-36. https://doi.org/10.1016/S0140-6736(08)61766-3
  4. Ayhan A, Yarali H, Urman B, et al (1989) Lymph node metastasis in early endometrium cancer. Aust N Z J Obstet Gynaecol, 29, 332-5. https://doi.org/10.1111/j.1479-828X.1989.tb01757.x
  5. Bassarak N, Blankenstein T, Bruning A, et al (2010). Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer, 10, 224. https://doi.org/10.1186/1471-2407-10-224
  6. Bell JG, Patterson DM, Klima J, et al (2014). Outcomes of patients with low-risk endometrial cancer surgically staged without lymphadenectomy based on intra-operative evaluation. Gynecol Oncol, 134, 505-9. https://doi.org/10.1016/j.ygyno.2014.06.028
  7. Ben-Shachar I, Pavelka J, Cohn DE, et al (2005). Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol, 105, 487-93. https://doi.org/10.1097/01.AOG.0000149151.74863.c4
  8. Benedetti Panici P, Basile S, Maneschi F, et al (2008). Systematic pelvic lymphadenectomy vs. no lymphadenectomy in earlystage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst, 100, 1707-16. https://doi.org/10.1093/jnci/djn397
  9. Chan JK, Cheung MK, Huh WK, et al (2006). Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer, 107, 1823-30. https://doi.org/10.1002/cncr.22185
  10. Chan JK, Wu H, Cheung MK, et al (2007). The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol, 106, 282-8. https://doi.org/10.1016/j.ygyno.2007.05.033
  11. De Wilde RL, Rafei A, Herrmann A (2014). Can a lymphadenectomy be avoided in early-stage endometrial adenocarcinoma? Arch Gynecol Obstet, 290, 973-8. https://doi.org/10.1007/s00404-014-3265-x
  12. Dowdy SC, Borah BJ, Bakkum-Gamez JN, et al (2012). Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol, 127, 5-10. https://doi.org/10.1016/j.ygyno.2012.06.035
  13. Eltabbakh GH, Piver MS, Hempling RE, Shin KH (1997). Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys, 38, 373-80. https://doi.org/10.1016/S0360-3016(97)00040-0
  14. Ferlay J, Soerjomataram I, Ervik M, et al GLOBOCAN (2012) v1.0 databases Cancer Incidence and Mortality Worldwide (http://globocan.iarc.fr).
  15. Fotiou S, Trimble EL, Papakonstantinou K, et al (2009). Complete pelvic lymphadenectomy in patients with clinical early, grade I and II endometrioid corpus cancer. Anticancer Res, 29, 2781-5.
  16. Goudge C, Bernhard S, Cloven NG, Morris P (2004). The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer. Gynecol Oncol, 93, 536-9. https://doi.org/10.1016/j.ygyno.2004.02.020
  17. Havrilesky LJ, Cragun JM, Calingaert B, et al (2005). Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol, 99, 689-95. https://doi.org/10.1016/j.ygyno.2005.07.014
  18. Hidaka T, Kato K, Yonezawa R, et al (2007). Omission of lymphadenectomy is possible for low-risk corpus cancer. Eur J Surg Oncol, 33, 86-90. https://doi.org/10.1016/j.ejso.2006.09.035
  19. Hidaka T, Nakashima A, Shima T, Hasegawa T, Saito S (2010). Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer. Obstet Gynecol Int, 2010, 490219.
  20. Homesley HD, Kadar N, Barrett RJ, Lentz SS (1992). Selective pelvic and periaortic lymphadenectomy does not increase morbidity in surgical staging of endometrial carcinoma. Am J Obstet Gynecol, 167, 1225-30. https://doi.org/10.1016/S0002-9378(11)91693-7
  21. Kang WD, Kim CH, Cho MK, et al (2009). Lymphadenectomy for low-risk endometrial cancer based on preoperative and intraoperative assessments. Int J Gynecol Cancer, 19, 657-61. https://doi.org/10.1111/IGC.0b013e3181a1319a
  22. Kumar S, Mariani A, Bakkum-Gamez JN, et al (2013). Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol, 130, 441-5. https://doi.org/10.1016/j.ygyno.2013.05.035
  23. Larson DM, Johnson KK (1993). Pelvic and para-aortic lymphadenectomy for surgical staging of high-risk endometrioid adenocarcinoma of the endometrium. Gynecol Oncol, 51, 345-8. https://doi.org/10.1006/gyno.1993.1301
  24. Mariani A, Webb MJ, Keeney GL, et al (2000). Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol, 182, 1506-19. https://doi.org/10.1067/mob.2000.107335
  25. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J (2010). Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev, 20, CD007585.
  26. NCCN clinical Practice Guidelines in Oncology databases. Uterine neoplasms V.1.2011 (http://www.nccn.org).
  27. Pecorelli S (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet, 105, 103-4. https://doi.org/10.1016/j.ijgo.2009.02.012
  28. Sethasathien P, Charoenkwan K, Siriaunkgul S (2014). Accuracy of intraoperative gross examination of myometrial invasion in stage I-II endometrial cancer. Asian Pac J Cancer Prev, 15, 7061-4. https://doi.org/10.7314/APJCP.2014.15.17.7061
  29. Singh M, Zaino RJ, Filiaci VJ, Leslie KK (2007). Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol, 106, 325-33. https://doi.org/10.1016/j.ygyno.2007.03.042
  30. Todo Y, Kato H, Kaneuchi M, et al (2010). Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet, 375, 1165-72. https://doi.org/10.1016/S0140-6736(09)62002-X
  31. Wang ZQ, Wang JL, Shen DH, Li XP, Wei LH (2013). Should all endometrioid uterine cancer patients undergo systemic lymphadenectomy? Eur J Surg Oncol, 39, 344-9. https://doi.org/10.1016/j.ejso.2012.12.007
  32. Vargas R, Rauh-Hain JA, Clemmer J, et al (2014). Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol, 133, 216-20. https://doi.org/10.1016/j.ygyno.2014.02.011
  33. Zhang C, Wang C, Feng W (2012). Clinicopathological risk factors for pelvic lymph node metastasis in clinical earlystage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer, 22, 1373-7. https://doi.org/10.1097/IGC.0b013e318269f68e